Merck recently proclaimed that the Phase 3 AMBASSADOR study assessing KEYTRUDA, an anti-PD-1 treatment developed by Merck.

In conjunction with Zealand Pharma A/S, Boehringer Ingelheim has initiated three Phase III research investigations for survodutide (also known as BI 456906)

First patient administered by Tenaya Therapeutics in MyPeak-1™ Phase 1b Clinical Trial for TN-201 treatment to address MYBPC3-Associated Hypertrophic Cardiomyopathy.

Oncternal Therapeutics starts administrating the first dose in phase 1/2 trial of ONCT-534, a dual-action AR inhibitor, for metastatic castration-resistant prostate cancer patients.

Janssen applies to the European Medicines Agency, seeking approval for using RYBREVANT (amivantamab) combined with chemotherapy to treat adults initially diagnosed with late-stage Non-Small Cell Lung Cancer with proficient EGFR Exon 20 Insertion Mutations.

The 2a trial of Rivus Pharmaceuticals' experimental metabolic booster, HU6, yielded promising results in treating High BMI individuals with Non-alcoholic Fatty Liver Disease.

Avidity Biosciences Reports Fresh Positive Results for AOC 1001, Showing Progress in Various Additional Functional Measures and Long-term Safety and Acceptability in Individuals with Type 1 Myotonic Dystrophy.

Bio-Thera Solutions has made it known that its associate company, Biogen, was recently notified by FDA about the approval of TOFIDENCE (tocilizumab-bavi) in an intravenous mixture.

Longeveron Inc. announced promising preliminary results from their Phase 2a trial with Lomecel-B™, aimed at treating mild Alzheimer’s disease.

Freeline Therapeutics reported positive preliminary results on safety, tolerability, and enzyme action from their ongoing Phase 1/2 GALILEO-1 study evaluating FLT201, their gene therapy candidate for Gaucher disease.

Nature reported on a discovery by AbbVie, the Broad Institute, and Calico Life Sciences. Their research indicates the potential of ABBV-CLS-484, an experimental drug, to act as a PTPN2/N1 phosphatase inhibitor boosting anti-cancer immunity, orally administered.

Moderna, Inc. reported encouraging preliminary outcomes from the mRNA-1083 Phase 1/2 study, a combination vaccine currently under investigation for its effect against both influenza and COVID-19.